Video

Dr. Shu on the MOA of Amivantamab in EGFR Exon 20 Insertion–Mutated NSCLC

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.

Catherine Ann Shu, MD, clinical director of Thoracic Medical Oncology Service, Department of Medicine, Division of Hematology/Oncology at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the mechanism of action of amivantamab (JNJ 61186372) in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.

The bispecific monoclonal antibody amivantamab was developed to simultaneously target 2 pathways that are the primary drivers in certain subpopulations of NSCLC, such as those with EGFR mutations and MET amplifications, Shu says. The agent has several unique mechanisms of action, Shu adds. By binding to the external domain of the EGFR receptor, its action is not dependent upon the nature of the activating mutation that typically occurs within the interior of the cell.

Moreover, EGFR exon 20 mutations pose a unique challenge in NSCLC despite being the third most common mutation, Shu says. This is due to the fact that patients with this mutation tend to be less sensitive to EGFR TKIs because of steric hindrance that occurs at the TKI binding site. The unique mechanism of action of amivantamab allows it to have activity against EGFR exon 20 mutations, Shu concludes.

In March 2020, amivantamab was granted a breakthrough therapy designation by the FDA in both the United States and China.

Related Videos
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.